<DOC>
	<DOCNO>NCT00193154</DOCNO>
	<brief_summary>In phase II trial , plan evaluate combination Tarceva Avastin treatment patient metastatic renal cell carcinoma . This trial one first phase II trial evaluate combination target agent treatment common solid tumor strong biologic rationale base Cancer Biology ( VHL/HIF/VEGF/EGFr ) .</brief_summary>
	<brief_title>OSI-774 Bevacizumab Treatment Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Tarceva + Avastin</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic unresectable clear cell kidney cancer confirm biopsy Previous nephrectomy Maximum 1 previous regimen metastatic disease Ability perform activity daily live minimal assistance Measurable disease Adequate bone marrow , liver kidney function Give write informed consent prior study entry You participate study follow apply : Age &lt; 18 year Treatment one previous regimen metastatic disease Clinically significant cardiovascular disease Active brain metastasis History CNS disease Clinical history cough vomit blood . History thromboembolic disease . PEG Gtube ineligible . Current use full dose anticoagulant thrombolytic agent Chronic daily treatment aspirin NSAIDS Any clinical evidence history bleed clot disorder Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Kidney Cancer</keyword>
</DOC>